HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

HAIXI PHARMA

201.000

-3.200-1.57%

Volume:105.00K

Turnover:21.02M

Market Cap:15.82B

PE:67.55

High:204.200

Open:201.000

Low:196.600

Close:204.200

52wk High:302.400

52wk Low:97.500

Shares:78.71M

HK Float Shares:78.71M

Volume Ratio:0.37

T/O Rate:0.13%

Dividend:- -

Dividend Rate:- -

EPS(LYR):2.976

ROE:16.58%

ROA:9.23%

PB:8.51

PE(LYR):67.55

PS:23.28

Loading ...

Overview Company News Filings

Stock Track | Haixi Pharma Soars 5.06% Intraday on Broker Buy Rating and Strong Drug Pipeline Progress

Stock Track | Haixi Pharma Soars 14.56% Intraday on First Broker Coverage and Pipeline Optimism

HAIXI PHARMA Surges Over 7% to Record High as HXP056 Nears Key Data Milestone

HAIXI PHARMA Shares Surge Over 4% as HXP056 Shows Significant Inhibition of Fundus Leakage; Potential to Reshape wAMD Treatment Landscape Upon Success

HAIXI PHARMA Maintains 78.71 Million Issued Shares in March 2026; Public Float Meets 25% Threshold

Bulletin Express

Three Undiscovered Asian Gems To Enhance Your Portfolio

Simply Wall St.

HAIXI PHARMA Shares Surge Over 8% Following Strong FY2025 Results

HAIXI PHARMA Reports 2025 Financial Results with Net Profit Jumping 30.09%

Haixi Pharma posts 30% profit jump in 2025, buoyed by generic drug sales and IPO proceeds

Bulletin Express

HAIXI PHARMA Shares Surge Over 4% in Morning Session as HXP056 Completes Phase I Enrollment and Initiates Phase II Study

Haixi Pharma completes Phase I enrollment for first-in-class oral wAMD drug HXP056; Phase II study underway

Bulletin Express

HAIXI PHARMA's Oral wAMD Drug Candidate HXP056 Concludes Phase I Enrollment and Advances to Phase II

Fujian Haixi Pharma starts Phase 2 China trial of HXP056 for wet age-related macular degeneration

HAIXI PHARMA (02637) Sets 30 Mar 2026 Board Meeting to Approve FY 2025 Results and Consider Final Dividend

Bulletin Express

HAIXI PHARMA (02637) Announces Appointment of Liu Guoxian as Joint Company Secretary, Authorized Representative, and Legal Process Agent

Fujian Haixi Pharmaceuticals appoints Lau Kwok Yin as joint company secretary

HAIXI PHARMA (02637) Announces February 2026 Monthly Return on Share Movements

Bulletin Express

Fujian Haixi Pharmaceuticals (2637) Announces New Senior Management Appointment

Bulletin Express

Fujian Haixi Pharmaceuticals Appoints Zhang Mingqiang as President of R&D and Global Affairs

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/02637/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"02637","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02637\",,,,,undefined,":{"symbol":"02637","market":"HK","secType":"STK","nameCN":"HAIXI PHARMA","latestPrice":201,"timestamp":1787299687040,"preClose":204.2,"halted":0,"volume":105000,"delay":0,"changeRate":-0.015670910871694362,"floatShares":78707270,"shares":78707270,"eps":2.975563205231751,"marketStatus":"Not Yet Opened","change":-3.2,"latestTime":"08-21 16:08:07","open":201,"high":204.2,"low":196.6,"amount":21020868,"amplitude":0.037218,"askPrice":206.8,"askSize":500,"bidPrice":201,"bidSize":550,"shortable":3,"etf":0,"ttmEps":2.9055499533439453,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1787535000000},"marketStatusCode":0,"adr":0,"listingDate":1760889600000,"exchange":"SEHK","adjPreClose":204.2,"openAndCloseTimeList":[[1787275800000,1787284800000],[1787288400000,1787299200000]],"volumeRatio":0.3655861566108926,"lotSize":50,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02637\",,,,,undefined,":{"symbol":"02637","floatShares":78707270,"roa":"9.23%","roe":"16.58%","lyrEps":2.975563,"volumeRatio":0.3655861566108926,"shares":78707270,"dividePrice":0,"high":204.2,"amplitude":0.037218,"preClose":204.2,"low":196.6,"week52Low":97.5,"pbRate":"8.51","psRate":"23.28","week52High":302.4,"institutionHeld":0,"latestPrice":201,"committee":0.047619,"eps":2.975563205231751,"divideRate":0,"volume":105000,"delay":0,"ttmEps":2.9055499533439453,"open":201,"prevYearClose":136,"prevWeekClose":204.8,"prevMonthClose":171,"prevQuarterClose":180,"fiveDayClose":204.8,"twentyDayClose":183.6,"sixtyDayClose":225.6,"earningDate":1787846400000},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02637\",params:#limit:5,,,undefined,":[{"date":"2026-08-28","symbol":"02637","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787880600000,"name":null,"time":"","dateTimestamp":1787846400000,"actualEps":null},{"date":"2026-03-30","symbol":"02637","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774834200000,"name":null,"time":"","dateTimestamp":1774800000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02637\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02637\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1781107200000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02637\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02637","date":"2026-08-21","current":69.177954,"percent":0.731707,"low":41.43616,"twenty":68.323237,"median":72.054899,"eighty":79.190679,"high":108.687128,"avg":73.776853,"sd":9.167145,"marketCap":15820161270},"quantilePoints":[{"date":"2025-10-16","current":41.43616,"twenty":41.43616,"median":41.43616,"eighty":41.43616,"marketCap":6150186077},{"date":"2025-10-24","current":58.044665,"twenty":53.788314,"median":54.742854,"eighty":58.044665,"marketCap":8618446065},{"date":"2025-10-31","current":63.409996,"twenty":54.11413,"median":58.177187,"eighty":60.582738,"marketCap":9429130946},{"date":"2025-11-07","current":65.038519,"twenty":55.071217,"median":59.875924,"eighty":63.533346,"marketCap":9665252756},{"date":"2025-11-14","current":69.713569,"twenty":57.493757,"median":61.562796,"eighty":68.778725,"marketCap":10389359640},{"date":"2025-11-21","current":66.575785,"twenty":58.2567,"median":64.026746,"eighty":69.208194,"marketCap":9917116020},{"date":"2025-11-28","current":68.072175,"twenty":59.478322,"median":65.807152,"eighty":68.767812,"marketCap":10176850011},{"date":"2025-12-05","current":68.42835,"twenty":59.854834,"median":66.893861,"eighty":68.767812,"marketCap":10247686554},{"date":"2025-12-12","current":69.403659,"twenty":60.326406,"median":67.279459,"eighty":69.361692,"marketCap":10412971821},{"date":"2025-12-19","current":69.502155,"twenty":61.237436,"median":67.861589,"eighty":69.423358,"marketCap":10452325456},{"date":"2025-12-24","current":72.521094,"twenty":61.537644,"median":68.055113,"eighty":69.462757,"marketCap":10940310530},{"date":"2026-01-02","current":68.547,"twenty":62.032842,"median":68.254334,"eighty":69.697511,"marketCap":10381488913},{"date":"2026-01-09","current":76.256401,"twenty":63.533346,"median":68.54394,"eighty":70.33117,"marketCap":11577839417},{"date":"2026-01-16","current":83.450154,"twenty":64.030428,"median":68.594109,"eighty":71.180851,"marketCap":12711224105},{"date":"2026-01-23","current":75.203122,"twenty":64.243828,"median":68.851274,"eighty":73.407226,"marketCap":11444037058},{"date":"2026-01-30","current":72.029156,"twenty":65.345972,"median":69.26967,"eighty":73.580372,"marketCap":11011147073},{"date":"2026-02-06","current":69.741329,"twenty":66.631937,"median":69.18814,"eighty":73.524909,"marketCap":10688447266},{"date":"2026-02-13","current":69.700471,"twenty":66.864009,"median":69.376262,"eighty":73.289662,"marketCap":10743542355},{"date":"2026-02-20","current":69.085102,"twenty":66.878935,"median":69.376262,"eighty":72.984771,"marketCap":10633352177},{"date":"2026-02-27","current":72.331605,"twenty":67.046254,"median":69.403659,"eighty":72.584608,"marketCap":11255139610},{"date":"2026-03-06","current":63.89376,"twenty":67.046254,"median":69.448144,"eighty":72.584608,"marketCap":9862020931},{"date":"2026-03-13","current":75.4784,"twenty":67.193436,"median":69.633279,"eighty":73.562991,"marketCap":11703771049},{"date":"2026-03-20","current":69.956787,"twenty":67.26348,"median":69.715081,"eighty":73.483508,"marketCap":10806508171},{"date":"2026-03-27","current":78.768036,"twenty":67.31702,"median":69.741329,"eighty":73.616705,"marketCap":12136661034},{"date":"2026-04-02","current":69.050489,"twenty":67.448055,"median":69.756887,"eighty":73.953025,"marketCap":13907574609},{"date":"2026-04-10","current":75.734842,"twenty":67.617502,"median":69.89051,"eighty":74.51958,"marketCap":15371529831},{"date":"2026-04-17","current":75.664292,"twenty":67.861589,"median":70.029272,"eighty":74.51958,"marketCap":15363659104},{"date":"2026-04-24","current":92.094347,"twenty":68.038051,"median":70.361759,"eighty":74.892793,"marketCap":18700847352},{"date":"2026-04-30","current":101.138303,"twenty":68.06535,"median":70.518529,"eighty":75.515578,"marketCap":20542597470},{"date":"2026-05-08","current":91.134409,"twenty":68.133872,"median":70.614497,"eighty":76.472636,"marketCap":18574915720},{"date":"2026-05-15","current":84.578883,"twenty":68.178204,"median":70.813553,"eighty":78.193464,"marketCap":17284116492},{"date":"2026-05-22","current":93.496946,"twenty":68.295676,"median":71.108793,"eighty":80.407586,"marketCap":19062900794},{"date":"2026-05-29","current":86.09458,"twenty":68.386305,"median":71.340959,"eighty":80.936301,"marketCap":17614687026},{"date":"2026-06-05","current":72.717092,"twenty":68.497704,"median":72.103769,"eighty":80.766638,"marketCap":14899286211},{"date":"2026-06-12","current":67.961351,"twenty":68.497704,"median":71.340959,"eighty":80.580489,"marketCap":13915445336},{"date":"2026-06-18","current":66.149737,"twenty":68.365282,"median":71.108793,"eighty":80.547429,"marketCap":13577004075},{"date":"2026-06-26","current":64.123676,"twenty":68.103023,"median":70.813553,"eighty":80.470686,"marketCap":13096889728},{"date":"2026-07-03","current":76.78307,"twenty":68.156523,"median":70.813553,"eighty":80.277662,"marketCap":15694229638},{"date":"2026-07-10","current":79.190679,"twenty":68.212992,"median":71.108793,"eighty":80.277662,"marketCap":16166473258},{"date":"2026-07-17","current":71.84101,"twenty":68.34426,"median":71.590985,"eighty":79.86919,"marketCap":14718259490},{"date":"2026-07-24","current":70.518964,"twenty":68.451468,"median":71.287767,"eighty":79.796901,"marketCap":14450654772},{"date":"2026-07-31","current":65.554893,"twenty":68.149296,"median":70.906272,"eighty":79.747346,"marketCap":13458943170},{"date":"2026-08-07","current":75.261161,"twenty":68.149296,"median":71.19828,"eighty":79.190679,"marketCap":15481720009},{"date":"2026-08-14","current":78.261297,"twenty":68.185431,"median":71.340959,"eighty":78.768036,"marketCap":16119248896},{"date":"2026-08-21","current":76.639812,"twenty":68.323237,"median":72.054899,"eighty":79.190679,"marketCap":15820161270}],"updateTime":1787500591469},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02637\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1141705590","title":"Stock Track | Haixi Pharma Soars 5.06% Intraday on Broker Buy Rating and Strong Drug Pipeline Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=1141705590","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141705590?lang=en_us&edition=fundamental","pubTime":"2026-04-28 09:48","pubTimestamp":1777340905,"startTime":"0","endTime":"0","summary":"Haixi Pharma's stock surged 5.06% during intraday trading on Tuesday, continuing its strong performance this year.The price movement follows Shenwan Hongyuan's initiation of coverage on the company...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120458534","title":"Stock Track | Haixi Pharma Soars 14.56% Intraday on First Broker Coverage and Pipeline Optimism","url":"https://stock-news.laohu8.com/highlight/detail?id=1120458534","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120458534?lang=en_us&edition=fundamental","pubTime":"2026-04-27 09:51","pubTimestamp":1777254687,"startTime":"0","endTime":"0","summary":"Haixi Pharma's stock surged 14.56% during intraday trading on Monday, marking a significant upward movement.The rally was primarily driven by Shenwan Hongyuan's first-ever coverage of the company,...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113832302","title":"HAIXI PHARMA Surges Over 7% to Record High as HXP056 Nears Key Data Milestone","url":"https://stock-news.laohu8.com/highlight/detail?id=1113832302","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1113832302?lang=en_us&edition=fundamental","pubTime":"2026-04-24 10:38","pubTimestamp":1776998304,"startTime":"0","endTime":"0","summary":"HAIXI PHARMA (02637) rose more than 7%, reaching an intraday high of HKD 230.4, a new record. At the time of writing, the stock was up 7.42% to HKD 228.8, with a turnover of HKD 53.3445 million. The...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK1191","02637","VXUS","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176595853","title":"HAIXI PHARMA Shares Surge Over 4% as HXP056 Shows Significant Inhibition of Fundus Leakage; Potential to Reshape wAMD Treatment Landscape Upon Success","url":"https://stock-news.laohu8.com/highlight/detail?id=1176595853","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176595853?lang=en_us&edition=fundamental","pubTime":"2026-04-17 11:10","pubTimestamp":1776395424,"startTime":"0","endTime":"0","summary":"HAIXI PHARMA (02637) rose more than 4%. At the time of writing, the stock was up 3.8%, trading at HK$196.6 with a turnover of HK$28.8643 million. The company previously announced that its innovative...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IPOS","VXUS","BK1191","BK4585","02637","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112407237","title":"HAIXI PHARMA Maintains 78.71 Million Issued Shares in March 2026; Public Float Meets 25% Threshold","url":"https://stock-news.laohu8.com/highlight/detail?id=1112407237","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1112407237?lang=en_us&edition=fundamental","pubTime":"2026-04-08 17:04","pubTimestamp":1775639074,"startTime":"0","endTime":"0","summary":"Fujian Haixi Pharmaceuticals Co., Ltd. (HAIXI PHARMA) filed its Monthly Return to Hong Kong Exchanges and Clearing for the period ended 31 March 2026, confirming no changes in either authorised or...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624828520","title":"Three Undiscovered Asian Gems To Enhance Your Portfolio","url":"https://stock-news.laohu8.com/highlight/detail?id=2624828520","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624828520?lang=en_us&edition=fundamental","pubTime":"2026-04-02 12:03","pubTimestamp":1775102626,"startTime":"0","endTime":"0","summary":"As geopolitical tensions and energy price volatility ripple through global markets, Asian equities are navigating a complex landscape with both challenges and opportunities. Amidst this backdrop, the S&P MidCap 400 and Russell 2000 indexes have shown resilience, highlighting the potential for small-cap stocks to thrive in uncertain times. In such an environment, identifying strong fundamentals and growth potential can be key to uncovering undiscovered gems that might enhance a diversified...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2637/fujian-haixi-pharmaceuticals-shares/news/three-undiscovered-asian-gems-to-enhance-your-portfolio","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2637/fujian-haixi-pharmaceuticals-shares/news/three-undiscovered-asian-gems-to-enhance-your-portfolio","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1191","02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108606328","title":"HAIXI PHARMA Shares Surge Over 8% Following Strong FY2025 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=1108606328","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108606328?lang=en_us&edition=fundamental","pubTime":"2026-04-01 10:20","pubTimestamp":1775010018,"startTime":"0","endTime":"0","summary":"HAIXI PHARMA (02637) saw its shares rise more than 8% after the company reported its financial results for the fiscal year 2025. As of the latest update, the stock was up 8.06%, trading at HK$172.9,...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637","BK4585","BK4588","BK1191","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100804736","title":"HAIXI PHARMA Reports 2025 Financial Results with Net Profit Jumping 30.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=1100804736","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100804736?lang=en_us&edition=fundamental","pubTime":"2026-03-31 00:20","pubTimestamp":1774887615,"startTime":"0","endTime":"0","summary":"HAIXI PHARMA (02637) has announced its financial results for 2025. The company reported revenue of approximately 582 million yuan, representing a year-on-year increase of 24.79%. Net profit reached...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184521353","title":"Haixi Pharma posts 30% profit jump in 2025, buoyed by generic drug sales and IPO proceeds","url":"https://stock-news.laohu8.com/highlight/detail?id=1184521353","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1184521353?lang=en_us&edition=fundamental","pubTime":"2026-03-30 22:43","pubTimestamp":1774881832,"startTime":"0","endTime":"0","summary":"Fujian Haixi Pharmaceuticals (Haixi Pharma) reported solid full-year results for 2025, underpinned by robust growth in its generic drug portfolio and strengthened by fresh capital from its October...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148445511","title":"HAIXI PHARMA Shares Surge Over 4% in Morning Session as HXP056 Completes Phase I Enrollment and Initiates Phase II Study","url":"https://stock-news.laohu8.com/highlight/detail?id=1148445511","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1148445511?lang=en_us&edition=fundamental","pubTime":"2026-03-25 10:38","pubTimestamp":1774406316,"startTime":"0","endTime":"0","summary":"HAIXI PHARMA (02637) saw its shares rise more than 4% during the morning trading session. At the time of writing, the stock was up 3.42%, trading at HKD 148, with a turnover of HKD 19.4604 million....","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","VXUS","02637","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193673628","title":"Haixi Pharma completes Phase I enrollment for first-in-class oral wAMD drug HXP056; Phase II study underway","url":"https://stock-news.laohu8.com/highlight/detail?id=1193673628","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1193673628?lang=en_us&edition=fundamental","pubTime":"2026-03-24 17:21","pubTimestamp":1774344070,"startTime":"0","endTime":"0","summary":"Fujian Haixi Pharmaceuticals Co., Ltd. (Haixi Pharma) announced the full enrollment of patients into both the single ascending dose and multiple ascending dose cohorts of its Phase I clinical trial...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187639991","title":"HAIXI PHARMA's Oral wAMD Drug Candidate HXP056 Concludes Phase I Enrollment and Advances to Phase II","url":"https://stock-news.laohu8.com/highlight/detail?id=1187639991","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1187639991?lang=en_us&edition=fundamental","pubTime":"2026-03-24 17:16","pubTimestamp":1774343796,"startTime":"0","endTime":"0","summary":"HAIXI PHARMA (02637) announced that its innovative drug candidate HXP056, a potential first-in-class oral medication for hemorrhagic retinal diseases, has completed patient enrollment for the Phase I...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621605091","title":"Fujian Haixi Pharma starts Phase 2 China trial of HXP056 for wet age-related macular degeneration","url":"https://stock-news.laohu8.com/highlight/detail?id=2621605091","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621605091?lang=en_us&edition=fundamental","pubTime":"2026-03-24 17:11","pubTimestamp":1774343471,"startTime":"0","endTime":"0","summary":"Haixi Pharmaceuticals said its oral wet age-related macular degeneration  candidate HXP056 has completed Phase 1 patient enrollment and has moved into a Phase 2 dose-expansion study in China.The company is positioning HXP056 as an oral alternative in retinal disease indications, which could broaden treatment access compared with injection-based care if later-stage trials support approval.Haixi Pharmaceuticals said the program is designed to support drug distribution to the retina, aiming to reduce development constraints that have limited oral approaches in this area.The company plans to use Phase 2 results to select an optimal dose to support a future Phase 3 study.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fujian Haixi Pharmaceu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nNDL1N0ttT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148839371","title":"HAIXI PHARMA (02637) Sets 30 Mar 2026 Board Meeting to Approve FY 2025 Results and Consider Final Dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=1148839371","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1148839371?lang=en_us&edition=fundamental","pubTime":"2026-03-10 16:44","pubTimestamp":1773132298,"startTime":"0","endTime":"0","summary":"Fujian Haixi Pharmaceuticals Co., Ltd. (HAIXI PHARMA, 02637) has scheduled a board meeting for Monday, 30 March 2026. The agenda includes: • Reviewing and approving the Group’s consolidated results...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175166735","title":"HAIXI PHARMA (02637) Announces Appointment of Liu Guoxian as Joint Company Secretary, Authorized Representative, and Legal Process Agent","url":"https://stock-news.laohu8.com/highlight/detail?id=1175166735","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1175166735?lang=en_us&edition=fundamental","pubTime":"2026-03-06 16:43","pubTimestamp":1772786581,"startTime":"0","endTime":"0","summary":"HAIXI PHARMA (02637) announced that Ms. Lin Huiyi has resigned from her positions as the company's Joint Company Secretary; the authorized representative of the company as stipulated under Rule 3.05...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617683673","title":"Fujian Haixi Pharmaceuticals appoints Lau Kwok Yin as joint company secretary","url":"https://stock-news.laohu8.com/highlight/detail?id=2617683673","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617683673?lang=en_us&edition=fundamental","pubTime":"2026-03-06 16:36","pubTimestamp":1772786187,"startTime":"0","endTime":"0","summary":"Fujian Haixi Pharmaceuticals Co. Ltd. said Sophie Lam Wai Yee has resigned as joint company secretary, authorised representative and process agent, effective 6 March 2026. The company appointed Lau Kwok Yin as joint company secretary, authorised representative and process agent from 6 March 2026. Lau is a vice president in the Listed Corporate Secretarial Department at SWCS Corporate Services Group  and has over 15 years of experience in corporate secretarial services, finance and banking operations. Zhang Junhuan will remain as joint company secretary.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fujian Haixi Pharmaceuticals Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Serv","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260306:nNDL5CfzpH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168367303","title":"HAIXI PHARMA (02637) Announces February 2026 Monthly Return on Share Movements","url":"https://stock-news.laohu8.com/highlight/detail?id=1168367303","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168367303?lang=en_us&edition=fundamental","pubTime":"2026-03-05 17:26","pubTimestamp":1772702807,"startTime":"0","endTime":"0","summary":"Fujian Haixi Pharmaceuticals Co., Ltd. (stock code: 02637) published its monthly return on movements in securities for the period ended 28 February 2026. The announcement indicates that the total...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145194990","title":"Fujian Haixi Pharmaceuticals (2637) Announces New Senior Management Appointment","url":"https://stock-news.laohu8.com/highlight/detail?id=1145194990","media":"Bulletin Express","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1145194990?lang=en_us&edition=fundamental","pubTime":"2026-03-01 18:25","pubTimestamp":1772360748,"startTime":"0","endTime":"0","summary":"Fujian Haixi Pharmaceuticals Co., Ltd. (Stock Code: 2637) announced the appointment of Dr. Zhang Mingqiang as President of Research & Development and Global Affairs, effective March 1, 2026. Dr....","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616821844","title":"Fujian Haixi Pharmaceuticals Appoints Zhang Mingqiang as President of R&D and Global Affairs","url":"https://stock-news.laohu8.com/highlight/detail?id=2616821844","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616821844?lang=en_us&edition=fundamental","pubTime":"2026-03-01 18:09","pubTimestamp":1772359768,"startTime":"0","endTime":"0","summary":"Fujian Haixi Pharmaceuticals Co. Ltd. has appointed Dr. Zhang Mingqiang as President of Research and Development and Global Affairs, effective 1 March 2026. Zhang previously held senior R&D leadership roles at Amgen, Merck Sharp and Dohme, Roche, and Biotica Technology.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fujian Haixi Pharmaceuticals Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 01, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260301:nNDL2kBCFp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1430594728.SGD","BK4533","LU2106854487.HKD","LU2360032135.SGD","SG9999014567.USD","LU1974910355.USD","LU0106261372.USD","BK4534","LU0980610538.SGD","LU0006306889.USD","LU2361045086.USD","SG9999001176.SGD","SG9999013999.USD","LU0965509283.SGD","LU1699723380.USD","SG9999001176.USD","LU0208291251.USD","LU0211331839.USD","BK1191","LU1934455863.HKD","LU1069347547.HKD","SG9999015341.SGD","LU1934455277.USD","LU0130517989.USD","LU1037948897.HKD","SG9999014542.SGD","LU1585245621.USD","LU1066051225.USD","LU1917777945.USD","LU0965509010.AUD","SG9999002224.SGD","LU2112291526.USD","LU1035773651.USD","LU1066051811.HKD","LU0058720904.USD","LU1941712264.USD","SGXZ57979304.SGD","LU0098860793.USD","LU2023250843.SGD","LU1061106388.HKD","IE000M9KFDE8.USD","LU0130102774.USD","LU2468319806.SGD","LU0985320562.USD","LU0265550359.USD","IE00BLSP4452.SGD","LU1057294990.SGD","IE00BN8TJ469.HKD","SG9999002232.USD","LU1941712348.USD","LU1989772840.SGD","BK4585","LU0861579265.USD","LU0234572021.USD","LU1989772923.USD","BK4588","IE0009355771.USD","LU0203345920.USD","LU2125154778.USD","IE00BJT1NW94.SGD","LU1291159041.SGD","IE00BLSP4239.USD","SG9999014559.SGD","BK4516","LU0122379950.USD","SG9999001440.SGD","LU0203347892.USD","LU1037948541.HKD","LU0238689110.USD","LU1201861249.SGD","LU0266013472.USD","LU2461242641.AUD","LU0289739699.SGD","LU1093756168.USD","LU0648001328.SGD","LU2361044865.SGD","IE00B2B36J28.USD","IE0002141913.USD","LU1116320737.USD","02637","LU1066053197.SGD","LU1571399168.USD","LU1116320901.HKD","IE00B4R5TH58.HKD","LU1023059063.AUD","LU1929549753.HKD","LU1989771016.USD","LU2324357040.USD","LU2361044949.HKD","IE00B1BXHZ80.USD","LU0265550946.USD","LU2023250504.SGD","BK4559","LU1162221912.USD","LU1983299246.USD","IE00BBT3K403.USD","IE00BSNM7G36.USD","LU0432979614.USD","LU0070302665.USD","SG9999015358.SGD","LU0965508806.USD","LU2089984988.USD","BK4550","LU1093756325.SGD","BK4007","LU2125154935.USD","LU0320765646.SGD","IE00BJJMRZ35.SGD","LU1066051498.USD","IE00BFTCPJ56.SGD","SG9999014575.USD","LU0477156953.USD","LU0965509101.SGD","LU1934455194.USD","LU0320765489.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":4,"totalSize":79,"code":"91000000","status":"200"}]}}